Australian biotechnology and life sciences online news source, BiotechDaily, reported that Regeneus received a non-refundable milestone payment of approximately $1.6 million (100 million Japanese Yen) from Kyocera Corporation as set out in the non-binding Memorandum of Understanding (MOU) signed on 2 March 2020.
- Tuesday, 24 March 2020
- Tuesday, 3 March 2020
Online investment publication Finfeed reported that Regeneus signed a non-binding memorandum of understanding (MOU) with Kyocera Corporation (Kyocera, TYO:6971), a diversified Japanese-based manufacturer with a strong position in the life sciences industry.
- Monday, 2 March 2020
The Market Herald - a leading source of authoritative breaking stock market news for self-directed investors - published an article reporting on Regeneus signing a non-binding memorandum of understanding with Kyocera Corporation.
- Monday, 6 January 2020
Regeneus AGC Agreement termination paves way for commercial partner
Regeneus’ CEO Leo Lee spoke with Boardroom Media to discuss the recent termination of our AGC agreement and what it means for potential partners for our lead candidate, Progenza OA in Japan.
- Thursday, 8 August 2019
Biotech Daily: Dr Boreham’s Crucible: Regeneus
By TIM BOREHAM
Flush with fresh funding, the stem cell play’s overhauled management is supremely confident of striking a partnering deal in Japan pertaining to its lead osteoarthritis treatment Progenza.